[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540033":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":150,"collaborators":26,"id":152,"slug":153,"hasResults":154,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":26,"eligibilityCriteria":158,"healthyVolunteers":154,"sex":159,"minAge":160,"maxAge":26,"enrollmentInfo":161,"targetDuration":26,"studyType":164,"phases":165,"briefSummary":167,"conditions":168,"keywords":26,"overallStatus":50,"whyStopped":26,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},{"fullName":5,"class":6},"Johnson & Johnson Enterprise Innovation Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Dose Escalation","EXPERIMENTAL","Participants with advanced solid tumors will receive JNJ-87704916 alone and in combination with cetrelimab. Ascending dose levels will be sequentially tested.",[13,14],"Drug: JNJ-87704916","Drug: Cetrelimab",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 2: Dose Expansion","Part 2 will consist of three cohorts: Cohort A, B and C. Participants in cohort A\\&B with metastatic non-small cell lung cancer (NSCLC) will receive JNJ-87704916 in combination with cetrelimab at the dose identified in Part 1. Cohort C will evaluate JNJ-87704916 treatment in combination with ongoing Standard of care (SoC) PD(L)-1 antibody therapy in frontline treatment of NSCLC.",[13,14,19],"Drug: Standard of Care PD(L)-1",[21,27,33],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","JNJ-87704916","JNJ-87704916 will be administered as an intratumoral injection.",[9,16],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Cetrelimab","Cetrelimab will be administered.",[9,16],[32],"JNJ-63723283",{"type":22,"name":34,"description":35,"armGroupLabels":36,"otherNames":26},"Standard of Care PD(L)-1","Frontline anti-PD(L)-1 antibody therapy will be administered as standard of care treatment.",[16],[38],{"name":39,"affiliation":5,"role":40},"Johnson & Johnson Enterprise Innovation Inc Clinical Trial","STUDY_DIRECTOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":26,"email":46},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[48,61,72,81,91,103,113,124,135,144],{"facility":49,"status":50,"city":51,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":26},"NYU Langone Health","RECRUITING","New York","10016","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-74.00597,40.71427,{"lat":59,"lon":58},{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":53,"countryCode":54,"cosmosGeoPoint":67,"geoPoint":71,"contacts":26},"Fox Chase Cancer Center","SUSPENDED","Philadelphia","Pennsylvania","19111",{"type":56,"coordinates":68},[69,70],-75.16362,39.95238,{"lat":70,"lon":69},{"facility":73,"status":50,"city":74,"state":65,"zip":75,"country":53,"countryCode":54,"cosmosGeoPoint":76,"geoPoint":80,"contacts":26},"UPMC Cancer Centers","Pittsburgh","15232",{"type":56,"coordinates":77},[78,79],-79.99589,40.44062,{"lat":79,"lon":78},{"facility":82,"status":50,"city":83,"state":84,"zip":85,"country":53,"countryCode":54,"cosmosGeoPoint":86,"geoPoint":90,"contacts":26},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":56,"coordinates":87},[88,89],-95.36327,29.76328,{"lat":89,"lon":88},{"facility":92,"status":50,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":26},"Toronto General Hospital","Toronto","Ontario","M5G 2C4","Canada","CA",{"type":56,"coordinates":99},[100,101],-79.39864,43.70643,{"lat":101,"lon":100},{"facility":104,"status":50,"city":105,"state":106,"zip":107,"country":96,"countryCode":97,"cosmosGeoPoint":108,"geoPoint":112,"contacts":26},"Centre Hospitalier de l'Universite de Montreal","Montreal","Quebec","H2X 0A9",{"type":56,"coordinates":109},[110,111],-73.58781,45.50884,{"lat":111,"lon":110},{"facility":114,"status":50,"city":115,"state":26,"zip":116,"country":117,"countryCode":118,"cosmosGeoPoint":119,"geoPoint":123,"contacts":26},"Gustave Roussy","Villejuif","94805","France","FR",{"type":56,"coordinates":120},[121,122],2.35992,48.7939,{"lat":122,"lon":121},{"facility":125,"status":50,"city":126,"state":26,"zip":127,"country":128,"countryCode":129,"cosmosGeoPoint":130,"geoPoint":134,"contacts":26},"Hosp Univ Vall D Hebron","Barcelona","08035","Spain","ES",{"type":56,"coordinates":131},[132,133],2.15899,41.38879,{"lat":133,"lon":132},{"facility":136,"status":50,"city":137,"state":26,"zip":138,"country":128,"countryCode":129,"cosmosGeoPoint":139,"geoPoint":143,"contacts":26},"Hosp Univ Fund Jimenez Diaz","Madrid","28040",{"type":56,"coordinates":140},[141,142],-3.70256,40.4165,{"lat":142,"lon":141},{"facility":145,"status":50,"city":137,"state":26,"zip":146,"country":128,"countryCode":129,"cosmosGeoPoint":147,"geoPoint":149,"contacts":26},"Hosp Univ Hm Sanchinarro","28050",{"type":56,"coordinates":148},[141,142],{"lat":142,"lon":141},{"type":151,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100540033","phase-1-a-study-of-jnj-87704916-as-monotherapy-and-in-combination-for-advanced-solid-tumors-100540033",false,"NCT06311578","A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors","Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors","Inclusion Criteria:\n\n* For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; Part 2: Individuals with histologically or cytologically confirmed metastatic or locally advanced NSCLC\n* Have at least 1 injectable tumor\n* Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1\n* A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study\n* Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy\n\nExclusion Criteria:\n\n* Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed\n* Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy\n* Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents\n* History of solid organ or hematologic stem cell transplantation\n* Known positive test result for human immunodeficiency virus (HIV) or other immunodeficiency syndrome\n* History of allergy to protein-based therapies or history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia)","ALL","18 Years",{"count":162,"type":163},126,"ESTIMATED","INTERVENTIONAL",[166],"PHASE1","The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.",[169],"Neoplasms","2026-06-04",{"date":172,"type":173},"2026-06-05","ACTUAL",{"date":175,"type":173},"2024-04-10",{"date":177,"type":163},"2032-08-26",{"name":5,"class":6},10]